Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancer
Authors:
- Junji FuruseJunji Furuse
- Takuji OkusakaTOTakuji Okusaka
- John BridgewaterJBJohn Bridgewater
- Masanori TaketsunaMTMasanori Taketsuna
- Harpreet WasanHWHarpreet Wasan
- Minori KoshijiMKMinori Koshiji
- Juan ValleJVJuan Valle
- 1 October 2011
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 80 (1) , 31-39
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009World Journal of Gastroenterology, 2009
- Gemcitabine-based versusfluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective studyBMC Cancer, 2008
- Epidemiology of biliary tract cancers: an updateAnnals of Oncology, 2008
- Difference in Biological Characteristics and Sensitivity to Chemotherapy and Radiotherapy Between Intrahepatic and Extrahepatic Cholangiocarcinoma Cells in VitroChinese Medical Sciences Journal, 2008
- Risk factors for cholangiocarcinomaEuropean Journal of Gastroenterology & Hepatology, 2007
- CholangiocarcinomaGastroenterology, 2005
- Combining Gemcitabine and Capecitabine in Patients With Advanced Biliary Cancer: A Phase II TrialJournal of Clinical Oncology, 2005
- Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinomaAnnals of Oncology, 2005
- Gemcitabine, 5‐fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinomaCancer, 2004
- Changing international trends in mortality rates for liver, biliary and pancreatic tumoursJournal of Hepatology, 2002